A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
NCT ID: NCT00234520
Last Updated: 2019-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
225 participants
OBSERVATIONAL
2003-05-31
2005-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Valvular Aortic Stenosis Prognosis Study
NCT03628313
Pressure Assessment to Improve Outcomes After TAVR: a Registry
NCT03923530
Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery.
NCT07099859
Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)
NCT04827238
Early Versus Deferred Aortic Valve Replacement in Patients With Moderate Aortic Stenosis and Mitral Regurgitation
NCT05310461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is being treated with lanreotide or octreotide in any dose form at the selection visit or is a de novo patient who is due to commence treatment within 2 weeks of baseline
* Patient started treatment with either lanreotide or octreotide when both products were available on the market in their country
* Patient must not change treatment form lanreotide to octreotide or vice versa for the duration of the study
Exclusion Criteria
* Patients who have received treatment with a somatostatin analogue other than lanreotide or octreotide for more than 3 months
* Patients who have received treatment with a GH antagonist for more than 3 months
* Patients who have had heart valve replacement therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliniques Universitaires Saint Luc
Brussels, , Belgium
UZ Gasthuisberg
Leuven, , Belgium
CHU de Liege
Liège, , Belgium
University Hospital, Charles University
Kralove, , Czechia
1st School of Medicine, Charles University
Prague, , Czechia
National University Hospital
Copenhagen, , Denmark
Hôpital de Bois
Bois-Guillaume, , France
Hôpital de la Timone
Marseille, , France
CHU de Brabois
Nancy, , France
Centre Hospitalier Régional d'Orléans
Orléans, , France
Hôpital du Haut-Lévêque
Pessac, , France
Hôpital Maison Blanche
Reims, , France
CHU de Rangueil
Toulouse, , France
Semmelweis University Medical School
Budapest, , Hungary
National Medical Center
Budapest, , Hungary
Ospedali Riuniti di Bergamo
Bergamo, , Italy
Università degli Studi di Ferrara
Ferrara, , Italy
Dipartimento di Scienze, Endocrinologiche e Metaboliche
Genova, , Italy
Università degli Studi di Milano
Milan, , Italy
University "Federico II" of Naples
Naples, , Italy
Clinica Medica II
Roma, , Italy
Bielanski Hospital
Warsaw, , Poland
Hospital General de Alicante
Alicante, , Spain
Clínica Puerta de Hierro
Madrid, , Spain
Fundación Jiménez Díaz
Madrid, , Spain
Research Centre for Endocrinology and Metabolism
Gothenburg, , Sweden
Endokrinologiska kliniken
Malmo, , Sweden
Karolinska Sjukhuset
Stockholm, , Sweden
Queen Elizabeth Medical Centre
Edgbaston, Birmingham, United Kingdom
Royal Free Hospital
Hampstead, , United Kingdom
Michael White Diabetes Centre
Hull, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Northern General Hospital
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008 Jun;93(6):2243-8. doi: 10.1210/jc.2007-2199. Epub 2008 Apr 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2-47-52030-721
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.